ConductScience.org, home

Paper20021320

Effect of second-generation antipsychotics on cognition: current issues and future challenges.

Hill SK and 3 others. Expert Rev Neurother, 2010. Cited by 185 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Papers, record 20021320. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20021320

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effect of second-generation antipsychotics on cognition: current issues and future challenges.
PubMed
Journal
Expert Rev Neurother
PubMed
Year
2010
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
185
iCite
Relative citation ratio, by iCite
5.64
iCite
Revised in PubMed
2025-05-29
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hill SKS Kristian
2Bishop JRJeffrey R
3Palumbo DDonna
4Sweeney JAJohn A

Source PubMed

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antipsychotic AgentsMajor topic
CognitionMajor topic
Cognition DisordersMajor topic
Animals
Disease Models, Animal
Humans
Neuropsychological Tests
Randomized Controlled Trials as Topic
Schizophrenia

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
K08 MH083888NIMH NIH HHSUnited StatesK08MH083888PubMed and NIHNIH RePORTER
K23 MH072767NIMH NIH HHSUnited StatesK23MH072767PubMed and NIHNIH RePORTER

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05130853Efficacy Study of a New Individualized Rehabilitation Programme for Social Cognition in Patients With SchizophreniaBackground

References111

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112,892,863The effects of atypical antipsychotic medications on psychosocial outcomes.Schizophr Res2003https://conductscience.org/library/papers/12892863PubMed
215,987,829Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine.J Pharmacol Exp Ther2005https://conductscience.org/library/papers/15987829PubMed
321,069Antipsychotic drugs: clinical pharmacology and therapeutic use.Drugs1977https://conductscience.org/library/papers/21069PubMed
416,271,709Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress.Brain Res2005https://conductscience.org/library/papers/16271709PubMed
515,784,157A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.Int J Neuropsychopharmacol2005https://conductscience.org/library/papers/15784157PubMed
617,548,746Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.Arch Gen Psychiatry2007https://conductscience.org/library/papers/17548746PubMed
79,673,998Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.Neuropsychology1998https://conductscience.org/library/papers/9673998PubMed
816,712,969The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats.Behav Brain Res2006https://conductscience.org/library/papers/16712969PubMed
910,942,847To model a psychiatric disorder in animals: schizophrenia as a reality test.Neuropsychopharmacology2000https://conductscience.org/library/papers/10942847PubMed
1018,536,701Effects of risperidone on procedural learning in antipsychotic-naive first-episode schizophrenia.Neuropsychopharmacology2009https://conductscience.org/library/papers/18536701PubMed
1119,389,335Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.J Clin Psychiatry2009https://conductscience.org/library/papers/19389335PubMed
1210,416,729The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.Schizophr Bull1999https://conductscience.org/library/papers/10416729PubMed
138,267,133The neuropsychological signature of schizophrenia: generalized or differential deficit?Am J Psychiatry1994https://conductscience.org/library/papers/8267133PubMed
1417,909,123Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?Arch Gen Psychiatry2007https://conductscience.org/library/papers/17909123PubMed
1512,680,740The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat.J Psychopharmacol2003https://conductscience.org/library/papers/12680740PubMed
1612,439,835Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia.Compr Psychiatry2002https://conductscience.org/library/papers/12439835PubMed
1712,827,347Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.Psychopharmacology (Berl)2003https://conductscience.org/library/papers/12827347PubMed
1810,227,104Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up.Schizophr Res1999https://conductscience.org/library/papers/10227104PubMed
1918,262,394Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex.Schizophr Res2008https://conductscience.org/library/papers/18262394PubMed
2017,507,917Clozapine normalizes prefrontal cortex dopamine transmission in monkeys subchronically exposed to phencyclidine.Neuropsychopharmacology2008https://conductscience.org/library/papers/17507917PubMed

See all 111 references

Cited by95

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 185 citations.

PMIDTitleJournalYearIn PapersSource
42,500,322Emerging non-D2 receptor-based therapies for schizophrenia: a focus on muscarinic and glutamatergic pathways.Front Psychiatry2026https://conductscience.org/library/papers/42500322PubMed
42,029,749Improving functioning in severe mental illness with cognitive remediation: study protocol for a pragmatic randomised multi-centre trial with adjunct sham-controlled tDCS (HEADDSET+).Eur Arch Psychiatry Clin Neurosci2026https://conductscience.org/library/papers/42029749PubMed
41,788,644Reversible aripiprazole-induced tardive dyskinesia: a case series from Saudi Arabia and literature review.Front Psychiatry2026https://conductscience.org/library/papers/41788644PubMed
41,168,741Exploring gut microbiota profile induced by antipsychotics in schizophrenic patients: insights from an Eastern European pilot study.BMC Psychiatry2025https://conductscience.org/library/papers/41168741PubMed
40,713,548Relationship between cognitive functions and serum neurotrophic factor levels in long-term hospitalized male patients with schizophrenia.BMC Psychiatry2025https://conductscience.org/library/papers/40713548PubMed
40,621,959Efficacy and safety of the muscarinic receptor agonist KarXT (Xanomeline-Trospium) in schizophrenia: a systematic review, meta-analysis and Bayesian sensitivity analysis.Int J Neuropsychopharmacol2026https://conductscience.org/library/papers/40621959PubMed
40,500,280Neuromodulation in the treatment of social cognition dysfunction in Schizophrenia: a systematic review.Schizophrenia (Heidelb)2025https://conductscience.org/library/papers/40500280PubMed
40,456,556Therapeutic Targeting of the α7 Nicotinic Receptor: Challenges and Prospects for Cognitive Improvement in Alzheimer's and Schizophrenia.Basic Clin Pharmacol Toxicol2025https://conductscience.org/library/papers/40456556PubMed
40,064,894Association between white blood cell counts and the efficacy on cognitive function after rTMS intervention in schizophrenia.Schizophrenia (Heidelb)2025https://conductscience.org/library/papers/40064894PubMed
39,732,701Effectiveness of a social cognition remediation intervention for patients with schizophrenia: a randomized-controlled study.Ann Gen Psychiatry2024https://conductscience.org/library/papers/39732701PubMed
39,718,691Drug-Induced Cognitive Impairment.Drug Saf2025https://conductscience.org/library/papers/39718691PubMed
39,564,115Knowledge domain and trends in treatment-resistant schizophrenia (TRS) research based on CiteSpace bibliometrics analysis.Front Pharmacol2024https://conductscience.org/library/papers/39564115PubMed
39,483,736The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia.Front Psychiatry2024https://conductscience.org/library/papers/39483736PubMed
39,377,784Biomarkers of cognitive and memory decline in psychotropic drug users.J Neural Transm (Vienna)2025https://conductscience.org/library/papers/39377784PubMed
39,205,914Adjunctive methylphenidate extended release in patients with schizophrenia: Protocol of a single-centre fixed dose cross-over open-label trial to improve functional and cognitive outcomes.Contemp Clin Trials Commun2024https://conductscience.org/library/papers/39205914PubMed
39,006,823The dynamic strategy shifting task: Optimisation of an operant task for assessing cognitive flexibility in rats.Front Psychiatry2024https://conductscience.org/library/papers/39006823PubMed
38,543,297Drug Repurposing of Metformin for the Treatment of Haloperidol-Related Behavior Disorders and Oxidative Stress: A Preliminary Study.Pharmaceutics2024https://conductscience.org/library/papers/38543297PubMed
38,487,578Association between CNS-active drugs and risk of Alzheimer's and age-related neurodegenerative diseases.Front Psychiatry2024https://conductscience.org/library/papers/38487578PubMed
37,386,462Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial.BMC Psychiatry2023https://conductscience.org/library/papers/37386462PubMed
36,925,354Human stem cell-based models to study synaptic dysfunction and cognition in schizophrenia: A narrative review.Schizophr Res2024https://conductscience.org/library/papers/36925354PubMed

See all 95 cited by

Genes16

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20021320

GET https://conductscience.org/api/papers/v1/20021320/references?page=2